Search Results
57 Results Found for “immunotherapy, ”
Prof. Amanda Piquet discusses the KYSA-8 miv-cel trial in refractory stiff-person syndrome, including efficacy findings, safety outcomes and the future role of CD19 CAR T-cell therapy in autoimmune neurologic disease. At the American Academy of Neurology Annual Meeting 2026, Prof. Amanda ...
Why this topic matters Autoimmune psychosis (AP) is conceptualized as a psychosis-dominant form of autoimmune encephalitis (AE). In contrast to ‘typical’ AE, in which seizures, impaired consciousness and focal deficits rapidly declare a neurological syndrome, patients with AP can initially ...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
The Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) 2026, held in Copenhagen, Denmark, brought together over 5,800 delegates to discuss advances across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders. ...
In this year-end review, we are pleased to share personal highlights from members of the touchNEUROLOGY Editorial Board, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
The 11th Congress of the European Academy of Neurology (EAN) delivered ground-breaking insights across neurology, showcasing how precision medicine is reshaping clinical practice. Taken from the EAN Highlights and Breaking news session presented 24 June 2025 (PLEN03), touchNEUROLOGY summarizes the key highlights across dementia, headache, movement disorders, cerebrovascular and neuromuscular diseases.
In this Q&A, Herbert Temmes shares why prevention is such a crucial and timely topic, how the MS community can be more involved in shaping decisions, and what outcomes he hopes the conference will deliver for years to come.
Neuromyelitis optica spectrum disorders (NMOSD) are a group of relapsing autoimmune diseases of the central nervous system. The clinical hallmarks of NMOSD are myelitis and optic neuritis; however, a wider clinical spectrum has been recognized.1Â The majority of patients with ...
Multiple sclerosis (MS) is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination and neurodegeneration. Natalizumab is a widely used anti-α4 integrin inhibitor for treating highly active MS. In the pivotal trials of natalizumab for MS, ...
Acute disseminated encephalomyelitis (ADEM), first characterized in 1931,1 is a non-specific clinical syndrome of polyfocal central nervous system (CNS) inflammatory demyelination; it is characterized by encephalopathy and large, poorly demarcated cerebral white matter lesions.2,3 Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD), ...
Myasthenia gravis (MG) represents the major and most frequent primary disorder of the neuromuscular junction. Clinical hallmarks are variable and include exercise-induced weakness involving extraocular, bulbar, limb and/or axial muscles.1Â Respiratory involvement, characterized by orthopnoea or dyspnoea with exertion, ...
Narcolepsy is a chronic clinical condition primarily characterized by excessive daytime sleepiness (EDS). This may be accompanied by cataplexy, which is a phenomenon of transient muscle weakness triggered by strong emotions, such as laughter, excitement, anger or grief. Narcolepsy is ...
The clinical use of cancer immunotherapy with immune checkpoint inhibitors (ICI) has transformed cancer management and added another effective treatment option for different types of malignancies.1–3 In 2018, the Nobel Prize for medicine and physiology was awarded for the discovery of ...
Watch three leading experts discuss diagnosis, treatment and care provision for patients with neuromyelitis optica spectrum disorder (NMOSD), with updates on the latest data for immunotherapy treatment options and guidance on how to support the holistic management of patients through multidisciplinary teams.
Lecanemab (BAN2401) is an amyloid-targeting monoclonal antibody currently in phase III clinical trials for prevention of Alzheimer’s disease (AD) in the AHEAD 3-45 study (ClinicalTrials.gov Identifier: NCT04468659)1 and for the treatment of early AD (mild cognitive impairment [MCI] ...
We had the pleasure of meeting with Yona Levites (Center for Translational Research in Neurodegenerative Disease, University of Florida, Gainesville, FL, USA ) to discuss her phase 1 study investigating the scFv-CD protein as a framework for identifying an optimized immunotherapy for ...
Neuromyelitis optica spectrum disorder (NMOSD) refers to a family of inflammatory central nervous system (CNS) diseases in which patients accrue disability through severe episodes of demyelination with typical manifestations including involvement of visual pathways (e.g., optic neuritis) and spinal ...
COVID-19 has become one of the greatest challenges in medical history, and the rapid development and approval of effective and safe treatments is essential to minimise the loss of lives during the pandemic. Given the urgency of finding effective strategies, ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
